1. Home

Entity Print

Krzysztof Kalwak
PDWP Chair (ELECTED APRIL 2023, PREVIOUS CHAIR: Selim Corbacioglu)
Germany

Major achievements

Leadership Change

In April 2023, Krzysztof Kalwak assumed the role of PDWP Chair, succeeding Selim Corbacioglu. Katharina Kleinschmidt was reconfirmed as Secretary.
Organisational Restructuring

The PDWP underwent a slight reorganisation, including updates to specific subcommittees and the establishment of new subcommittees such as Young Investigators and PICU (see organigram).

Educational Initiatives

The PDWP prioritised educational efforts this year, participating at two significant events:

- **Midterm Meeting on Immune Diseases**: Held from June 22 - 24 in Brescia, Italy, this event brought together three EBMT working parties to discuss therapeutic approaches to immune dysregulatory, autoinflammatory, and autoimmune diseases. The meeting aimed to facilitate interdisciplinary discussions among transplant physicians and disease specialists to evaluate transplant and cellular therapy options.

- **International Transplant Course**: The eighth edition of this course took place in September, 2023 in Barcelona, Spain. Notably, a dedicated paediatric track was included in this edition, occupying nearly one day. Future editions aim to further expand the paediatric program to establish a one and a half day event.

Registry Data Quality Improvement

A major focus of the PDWP is to enhance the quality of registry-based data. Currently, over 20 PDWP studies are either under evaluation or already ongoing, emphasizing the commitment to advancing research in the field.

Prospective Trials

The PDWP plans to intensify collaborative international prospective trials in the coming years, underscoring the commitment to driving forward research and clinical advancements in paediatric transplant and cellular therapy.

Overall, the PDWP's activities and initiatives demonstrate a multifaceted approach to advancing knowledge, enhancing education, improving data quality, and fostering collaboration in the field of paediatric transplantation and cellular therapy.
Principal research studies

Phase 2 trial to assess haploidentical α/β T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor (T-Haplo-HSCT for SCD)

Study type

Diseases
Other non-malignant disorders

Group
Paediatric Diseases Working Party (PDWP)

Type of Stem Cell Treatment
Allogeneic - Haploidentical

Principal investigator
Selim Corbacioglu

Outcome of children developing grade III-IV aGVHD after allogeneic HSCT

Study type
Retrospective Studies

Diseases
Acute Myeloid Leukaemia (AML)

Group
Paediatric Diseases Working Party (PDWP)

Type of Stem Cell Treatment
Allogeneic

Principal investigator
Giovanna Lucchini

Impact of AB0 Incompatibility on HSCT outcome in hemoglobinopathies: A Retrospective Registry Study from the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Study type
Retrospective Studies

Diseases
Other non-malignant disorders

Group
Paediatric Diseases Working Party (PDWP)
Haemoglobinopathies Working Party (HWP)
Type of Stem Cell Treatment
Allogeneic
Principal investigator
Katharina Kleinschmidt
Myeloablative conditioning for allo-HSCT in pediatric ALL and AML below 2 years
Study type
Retrospective Studies
Diseases

- Group
Paediatric Diseases Working Party (PDWP)
Type of Stem Cell Treatment

- Principal investigator
André Willasch
Prevention and management of conditioning related skin toxicity in paediatric HSCT patients
Study type

- Diseases

- Group
Nursing Research Committee
Nursing Paediatric Committee
Paediatric Diseases Working Party (PDWP)
Type of Stem Cell Treatment

- Principal investigator
Mihaela Hartmann

**Key publications**

2023
Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study Group
Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study

Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties

Decision making on HSCT in patients with hemoglobinopathies; an EBMT Pediatric Diseases Working Party and Inborn Errors Working Party scenario-based survey on physicians' perspectives
2021 2022 2023

Oral presentations  1  10  2
Poster presentations  1  3  2
Educational events  1  1  1
**Event**

**49th Annual Meeting of the EBMT**

**Event**

**Midterm Meeting on New indications in Immune Dysregulatory, Autoinflammatory and Autoimmune Diseases**

**Jun 22, 2023 - Jun 24, 2023 / Brescia, Italy**

**Discover more**
Event

8th International Transplant and Cellular Therapy Course

Sep 08, 2023 - Sep 10, 2023 / Barcelona, Spain

Discover more
VISIT THE PDWP WEBPAGE